E E A Arts1, C D Popa2, A A Den Broeder3, R Donders4, A Sandoo5, T Toms5, S Rollefstad6, E Ikdahl6, A G Semb6, G D Kitas5, P L C M Van Riel7, J Fransen1. 1. Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands Department of Rheumatology, Bernhoven Hospital, Uden, The Netherlands. 3. Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands. 4. Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Medical Center, Nijmegen, The Netherlands. 5. Department of Rheumatology, Dudley Group NHS Foundation Trust, Dudley, UK. 6. Preventive Cardio-Rheuma Clinic, Diakonhjemmet Hospital, Oslo, Norway. 7. Department of Rheumatology, Bernhoven Hospital, Uden, The Netherlands Radboud Institute for Health Sciences, IQ healthcare, Radboud University Medical Center, Nijmegen, The Netherlands.
Abstract
OBJECTIVES: Predictive performance of cardiovascular disease (CVD) risk calculators appears suboptimal in rheumatoid arthritis (RA). A disease-specific CVD risk algorithm may improve CVD risk prediction in RA. The objectives of this study are to adapt the Systematic COronary Risk Evaluation (SCORE) algorithm with determinants of CVD risk in RA and to assess the accuracy of CVD risk prediction calculated with the adapted SCORE algorithm. METHODS: Data from the Nijmegen early RA inception cohort were used. The primary outcome was first CVD events. The SCORE algorithm was recalibrated by reweighing included traditional CVD risk factors and adapted by adding other potential predictors of CVD. Predictive performance of the recalibrated and adapted SCORE algorithms was assessed and the adapted SCORE was externally validated. RESULTS: Of the 1016 included patients with RA, 103 patients experienced a CVD event. Discriminatory ability was comparable across the original, recalibrated and adapted SCORE algorithms. The Hosmer-Lemeshow test results indicated that all three algorithms provided poor model fit (p<0.05) for the Nijmegen and external validation cohort. The adapted SCORE algorithm mainly improves CVD risk estimation in non-event cases and does not show a clear advantage in reclassifying patients with RA who develop CVD (event cases) into more appropriate risk groups. CONCLUSIONS: This study demonstrates for the first time that adaptations of the SCORE algorithm do not provide sufficient improvement in risk prediction of future CVD in RA to serve as an appropriate alternative to the original SCORE. Risk assessment using the original SCORE algorithm may underestimate CVD risk in patients with RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: Predictive performance of cardiovascular disease (CVD) risk calculators appears suboptimal in rheumatoid arthritis (RA). A disease-specific CVD risk algorithm may improve CVD risk prediction in RA. The objectives of this study are to adapt the Systematic COronary Risk Evaluation (SCORE) algorithm with determinants of CVD risk in RA and to assess the accuracy of CVD risk prediction calculated with the adapted SCORE algorithm. METHODS: Data from the Nijmegen early RA inception cohort were used. The primary outcome was first CVD events. The SCORE algorithm was recalibrated by reweighing included traditional CVD risk factors and adapted by adding other potential predictors of CVD. Predictive performance of the recalibrated and adapted SCORE algorithms was assessed and the adapted SCORE was externally validated. RESULTS: Of the 1016 included patients with RA, 103 patients experienced a CVD event. Discriminatory ability was comparable across the original, recalibrated and adapted SCORE algorithms. The Hosmer-Lemeshow test results indicated that all three algorithms provided poor model fit (p<0.05) for the Nijmegen and external validation cohort. The adapted SCORE algorithm mainly improves CVD risk estimation in non-event cases and does not show a clear advantage in reclassifying patients with RA who develop CVD (event cases) into more appropriate risk groups. CONCLUSIONS: This study demonstrates for the first time that adaptations of the SCORE algorithm do not provide sufficient improvement in risk prediction of future CVD in RA to serve as an appropriate alternative to the original SCORE. Risk assessment using the original SCORE algorithm may underestimate CVD risk in patients with RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Jon T Giles; Mary Chester M Wasko; Cecilia P Chung; Moyses Szklo; Roger S Blumenthal; Amy Kao; Sabahat Bokhari; Afshin Zartoshti; C Michael Stein; Joan M Bathon Journal: Arthritis Rheumatol Date: 2019-08-01 Impact factor: 10.995
Authors: Vital Da Silva Domingues; Ana M Rodrigues; Sara S Dias; Luís Delgado; Ebrahim Barkoudah; Jaime Branco; Helena Canhão Journal: Rheumatol Int Date: 2021-01-03 Impact factor: 2.631
Authors: Cynthia S Crowson; Sherine E Gabriel; Anne Grete Semb; Piet L C M van Riel; George Karpouzas; Patrick H Dessein; Carol Hitchon; Virginia Pascual-Ramos; George D Kitas Journal: Rheumatology (Oxford) Date: 2017-07-01 Impact factor: 7.580
Authors: Narendra N Khanna; Ankush D Jamthikar; Deep Gupta; Matteo Piga; Luca Saba; Carlo Carcassi; Argiris A Giannopoulos; Andrew Nicolaides; John R Laird; Harman S Suri; Sophie Mavrogeni; A D Protogerou; Petros Sfikakis; George D Kitas; Jasjit S Suri Journal: Curr Atheroscler Rep Date: 2019-01-25 Impact factor: 5.113